Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

This was the stock's third consecutive day of losses.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The stock's fall snapped a three-day winning streak.

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes ...

According to a Worker Adjustment Retraining Notification written by Vertex to the R.I. Department of Labor and Training, ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...